(NASDAQ: GERN) Geron's forecast annual revenue growth rate of 27.19% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 99.6%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.68%.
Geron's revenue in 2025 is $183,403,000.On average, 9 Wall Street analysts forecast GERN's revenue for 2025 to be $121,606,679,888, with the lowest GERN revenue forecast at $115,797,646,885, and the highest GERN revenue forecast at $125,902,810,888. On average, 9 Wall Street analysts forecast GERN's revenue for 2026 to be $169,547,161,040, with the lowest GERN revenue forecast at $147,211,109,968, and the highest GERN revenue forecast at $196,243,178,641.
In 2027, GERN is forecast to generate $246,175,328,251 in revenue, with the lowest revenue forecast at $186,827,438,334 and the highest revenue forecast at $294,186,028,484.